MARÍA DOLORES
CABALLERO BARRIGÓN
Investigadora en el periodo 1998-2022
Tel Aviv University
Tel Aviv, IsraelPublicaciones en colaboración con investigadores/as de Tel Aviv University (4)
2021
-
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Leukemia, Vol. 35, Núm. 12, pp. 3585-3588
2020
-
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study
British Journal of Haematology, Vol. 189, Núm. 1, pp. 84-96
2019
-
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
The Lancet Haematology, Vol. 6, Núm. 2, pp. e67-e78
2017
-
Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
Journal of Clinical Oncology, Vol. 35, Núm. 22, pp. 2473-2481